<DOC>
	<DOCNO>NCT01484587</DOCNO>
	<brief_summary>The purpose study assess safety tolerability CNTO 1959 follow single subcutaneous ( SC , skin ) dose administer Japanese participant moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics ( What Body Does Drug ) , Pharmacodynamics ( What Drug Does Body ) CNTO 1959 Following Single Subcutaneous ( Under Skin ) Administration Japanese Participants With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>This randomize ( participant assign treatment group chance ) , double-blind ( participant study personnel know study agent give ) , placebo-controlled ( placebo treatment identical appearance CNTO 1959 contain active drug ) , single-dose study . The study include 24 participant : 4 group least 6 participant . If decided additional data need define safety tolerability CNTO 1959 , additional group may enrol . A give dose level may repeat newly enrol participant , low intermediate dose may administer base preliminary data . The total duration participation approximately 30 week , include screening period 6 week administration study agent . Participant safety monitor . Ascending dose 10 , 30 , 100 , 300 mg dose CNTO 1959 placebo administer single SC injection ; however , 2 SC injection may require 300 mg dose level . Dosing perform 24 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis plaquetype psoriasis least 6 month prior screen ( participant concurrent psoriatic arthritis may enrol ) Having plaquetype psoriasis cover least 10 % total body surface area ( BSA ) baseline Has Psoriasis Area Severity Index ( PASI ) score 12 great baseline Is candidate systemic phototherapy systemic treatment psoriasis ( either new treatment previous treatment ) Has least 2 plaque suitable repeat biopsy ( Only participant consent separately participate assessment . Refusal give consent component exclude individual participation clinical study ) . Currently nonplaque form psoriasis ( eg , erythrodermic , guttate , pustular ) Has current druginduced psoriasis ( e.g. , new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) Has history chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection ( e.g. , secondary infection occur bronchiectasis ) , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , open , drain , infected skin wound ulcer Has history latent , active opportunistic systemic infection pathogen include , limited , Klebsiella pneumoniae , Cryptococcus neoformans , Candida albicans , Toxoplasma gondii , Pneumocystis jiroveci prior screening Has serious infection ( e.g. , sepsis , pneumonia pyelonephritis ) , hospitalize receive intravenous antibiotic infection 2 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Moderate Severe Plaque-Type Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque-type psoriasis</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>Japanese participant</keyword>
</DOC>